Table 2.

Clinicopathological features and NFATc1 expression in patients with stage IE/IIE1 gastric MALT lymphoma who received first-line HPE therapy

	Nuclear localization of NFATc1
Clinicopathological characteristics	Total number (n = 91)	Presence (n = 51)	Absence (n = 40)	p*
Age (median, range, years)	56.0 (20–86)	57.0 (30–83)	55.0 (20–86)	0.608#
Sex, men/women	38/53	21/30	17/23	0.899§
Endoscopic features, n (%)				0.289‡
Gastritis-like or multiple erosion on infiltrative mucosa	35 (38%)	19 (37%)	16 (40%)
Ulceration or ulcerated mass	40 (44%)	20 (39%)	20 (50%)
Erosions on giant nodular folds	16 (18%)	12 (24%)	4 (10%)
Location of lymphoma(s), n (%)				0.570§
Proximala or ≥ 2 components	29 (32%)	15 (29%)	14 (35%)
Distalb	62 (68%)	36 (71%)	26 (65%)
Stage				0.537§
IE	70 (77%)	38 (75%)	32 (80%)
IIE1	21 (23%)	13 (25%)	8 (20%)
Depth of gastric wall involvement, n (%)¶				0.380§
Submucosa or above	52/86 (60%)	31/48 (65%)	21/38 (55%)
Muscularis propria or beyond	34/86 (40%)	17/48 (35%)	17/38 (45%)
CagA expression				< 0.001§
Positive	54 (59%)	41 (80%)	13 (33%)
Negative	37 (41%)	10 (20%)	27 (67%)
T(11;18)(q21;q21)/BIRC3-MALT1				0.002
Positive	10 (11%)	1 (2%)	9 (23%)
Negative	81 (89%)	50 (98%)	31 (77%)

p*: comparison of discrete variables between NFATc1-positive cases and NFATc1-negative cases

^#p values (two-sided) were calculated using the Student’s t-test

^§p values (two-sided) were calculated using Chi-square test or Fisher’s exact test

^‡p values (two-sided) were calculated using one-way analysis of variance

Proximal^a: Middle body, upper body, fundus, or cardia. Distal^b: Antrum, angle, or lower body

Gastric wall involvement was evaluated by endoscopic ultrasonography in 86 patients

HPE Helicobacter pylori eradication therapy, MALT mucosa-associated lymphoid tissue